Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Deck updated

<< Previous

Bullboard Posts

Next >>

Comment by 3burtcon Feb 03, 2021 12:09pm

162 Views

Post# 32458931

RE:RE:Deck updated

Other drugs are irrelevant, they have nothing to do with otena. 10 billion should be easily with ate capturing over 50 % of the market and then who knows ? Will the fda ask for removal of the dangerous nsaids? Possibly. Glta, looking forward to 400 bucks in 2025.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"